Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of...

Full description

Saved in:
Bibliographic Details
Main Authors Blake, James F, McNulty, Oren T, Andrews, Steven W, McKenney, Megan L, McFaddin, Elizabeth A, Haas, Julia, Kolakowski, Gabrielle R, Tang, Tony P, Brandhuber, Barbara J, Metcalf, Andrew T, Ren, Li, Jiang, Yutong, Cook, Adam, Moreno, David A, Aronow, Sean
Format Patent
LanguageEnglish
Published 08.01.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Bibliography:Application Number: US201815860808